Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Jacobi Capital Management LLC Acquires New Stake in Glaukos Corp (NYSE:GKOS)
09:30am, Saturday, 01'st Aug 2020
Jacobi Capital Management LLC acquired a new stake in Glaukos Corp (NYSE:GKOS) during the 2nd quarter, Holdings Channel reports. The fund acquired 1,000 shares of the medical instruments supplier’s
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
04:33pm, Thursday, 30'th Jul 2020
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6
11:00am, Monday, 20'th Jul 2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to
Glaukos Corp (NYSE:GKOS) Shares Sold by Invesco Ltd.
05:26am, Monday, 06'th Jul 2020
Invesco Ltd. reduced its position in Glaukos Corp (NYSE:GKOS) by 62.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned
Microkeratome Market to Surpass US$ 1,347.0 Million globally by end of 2027, Says CMI
12:00am, Friday, 03'rd Jul 2020
Increasing adoption of microkeratome procedures coupled with the rising number of age-related disorders.
Here is What Hedge Funds Think About Glaukos Corporation (GKOS)
09:43pm, Sunday, 28'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Thrivent Financial for Lutherans Makes New Investment in Glaukos Corp (NYSE:GKOS)
06:57am, Friday, 26'th Jun 2020
Thrivent Financial for Lutherans bought a new stake in Glaukos Corp (NYSE:GKOS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C
Here's Why You Should Retain Glaukos in Your Portfolio Now
11:43am, Thursday, 18'th Jun 2020
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
Glaukos Corp (NYSE:GKOS) to Post Q2 2020 Earnings of ($0.80) Per Share, Jefferies Financial Group Forecasts
07:08am, Wednesday, 17'th Jun 2020
Glaukos Corp (NYSE:GKOS) – Stock analysts at Jefferies Financial Group issued their Q2 2020 earnings per share estimates for Glaukos in a research note issued on Monday, June 15th. Jefferies Financi
Glaukos (NYSE:GKOS) Coverage Initiated by Analysts at Jefferies Financial Group
07:30am, Tuesday, 16'th Jun 2020
Jefferies Financial Group initiated coverage on shares of Glaukos (NYSE:GKOS) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a hold rating and a $44.00 price
BNP Paribas Arbitrage SA Lowers Stake in Glaukos Corp (NYSE:GKOS)
08:38am, Sunday, 14'th Jun 2020
BNP Paribas Arbitrage SA cut its stake in Glaukos Corp (NYSE:GKOS) by 43.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The instituti
Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference
10:30pm, Tuesday, 09'th Jun 2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes
02:42am, Tuesday, 09'th Jun 2020
Glaukos Corporation (NYSE: GKOS) (the "Company" or "Glaukos"), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders a
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes
12:00am, Tuesday, 09'th Jun 2020
Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies
Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
11:06am, Monday, 08'th Jun 2020
Glaukos Corporation (NYSE: GKOS) (the "Company" or "Glaukos"), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders a
